UltraSight
HealthTech & Life SciencesUltraSight develops AI software that guides clinicians while acquiring cardiac ultrasound images.
Introduce me to UltraSight
Image source: company website sharing image
Founders & company facts
Sources reviewed:Reported cumulative funding
$15,200,000 · Source
This index includes companies with publicly reported total funding up to US$150 million. This is a reported total, not valuation, the latest round size or confirmation of an open round. Funding reviewed: .
Documented founding team
- Achiau LudomirskySource: Achiau Ludomirsky
- Yaron LipmanSource: Yaron Lipman
- Itay KezurerSource: Itay Kezurer
- Founded
- 2019Source
- Reported Israeli location
- Ness ZionaSource
- Team range in directory
- 11-50Source
- Reported business model
- B2BSource
Selected disclosed financing
Selected transactions, with dates, funding types and reported participants.
- May 2021$13MSeries B
- Oct 2020$200KNon-equity funding
Company overview
Product & customers
UltraSight develops AI software that guides clinicians while acquiring cardiac ultrasound images. Its focus is the image-capture step, helping users position the probe and obtain usable views.
Commercial potential · editorial analysis
The commercial opportunity is expanding access to cardiac imaging by helping a wider range of trained healthcare professionals acquire consistent examinations. Investors should distinguish paid use and renewals from pilots, and examine how sales and delivery costs change as deployments expand.
What to validate
Diligence should focus on clearance for each intended use, performance by operator experience, device compatibility and downstream diagnostic review. Evidence should come from representative customer deployments, with costs, limitations and failure cases reported alongside successful results.
Product source reviewed on . Company source